Directorate for Research, Studies and Documentation, National Public Health Organization, Athens, Greece.
Pharmacotherapy Outcomes Research Center, College of Pharmacy, University of Utah, Salt Lake City, UT, USA.
J Hosp Infect. 2021 Aug;114:126-133. doi: 10.1016/j.jhin.2021.04.018. Epub 2021 Apr 22.
Healthcare personnel (HCP) are at increased risk of infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the aetiological agent of coronavirus disease 2019 (COVID-19).
To estimate the costs related to SARS-CoV-2 exposure and infection among HCP in Greece.
Data were retrieved from the national database of SARS-CoV-2 infections and from the database of HCP exposed to patients with COVID-19. A cost-of-illness analysis was performed to estimate total, direct and indirect costs.
In total, 254 HCP with COVID-19 and 3332 HCP exposed to patients with COVID-19 during the first epidemic wave were studied. Of the 254 HCP with COVID-19, 49 (19.3%) were hospitalized (mean length of hospitalization 11.6 days) and four were admitted to intensive care units (mean duration 10.8 days). Overall, 1332 (40%) exposed HCP had a mean duration of absenteeism of 7.5 days, and 252 (99.2%) HCP with COVID-19 had a mean duration of absenteeism of 25.8 days. The total costs for the management of the two groups were estimated at €1,735,830 (€772,890 Euros for HCP with COVID-19 and €962,940 for exposed HCP). Absenteeism accounted for a large proportion of the total costs (80.4% of all expenditures), followed by costs for reverse transcriptase polymerase chain reaction and hospitalization (10.2% and 6.5% of all expenditures, respectively).
COVID-19 is associated with increased rates and duration of absenteeism among HCP. Indirect costs, particularly absenteeism, are the major driver of total costs among exposed HCP and HCP with COVID-19. The estimated total costs are conservative. Studies are needed to explore the impact of COVID-19 vaccination of HCP on absenteeism and COVID-19-associated costs.
医疗保健人员(HCP)感染严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的风险增加,SARS-CoV-2 是导致 2019 年冠状病毒病(COVID-19)的病原体。
估计希腊 HCP 因 SARS-CoV-2 暴露和感染而产生的相关成本。
从 SARS-CoV-2 感染国家数据库和 COVID-19 患者接触的 HCP 数据库中检索数据。进行疾病成本分析以估计总费用、直接费用和间接费用。
在首次疫情期间,共研究了 254 名 COVID-19 医护人员和 3332 名接触 COVID-19 患者的医护人员。在 254 名 COVID-19 医护人员中,49 人(19.3%)住院(平均住院时间为 11.6 天),4 人入住重症监护病房(平均持续时间为 10.8 天)。总体而言,1332 名(40%)暴露医护人员平均缺勤 7.5 天,252 名(99.2%)COVID-19 医护人员平均缺勤 25.8 天。管理这两个群体的总成本估计为 1735830 欧元(COVID-19 医护人员为 772890 欧元,接触 COVID-19 的医护人员为 962940 欧元)。缺勤占总费用的很大比例(占所有支出的 80.4%),其次是逆转录聚合酶链反应和住院费用(分别占所有支出的 10.2%和 6.5%)。
COVID-19 导致 HCP 缺勤率和缺勤时间增加。间接成本,特别是缺勤,是接触 COVID-19 的医护人员和 COVID-19 医护人员总费用的主要驱动因素。估计的总成本是保守的。需要研究 COVID-19 疫苗接种对 HCP 缺勤和 COVID-19 相关成本的影响。